Correction to: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma (Journal of Hematology & Oncology, (2024), 17, 1, (128), 10.1186/s13045-024-01636-4)

Hose, D., Ray, S., Rößler, S., Thormann, U., Schnettler, R., de Veirman, K., Khassawna, T. E., Heiss, C., Hild, A., Zahner, D., Alagboso, F., Henss, A., Beck, S., Emde-Rajaratnam, M., Burhenne, J., Bamberger, J., Menu, E., de Bruyne, E., Gelinsky, M., Kampschulte, M., & 6 othersRohnke, M., Wenisch, S., Vanderkerken, K., Hanke, T., Seckinger, A. & Alt, V., 24 Jan 2025, In: Journal of Hematology & Oncology. 18, 1, 1 p., 11.

Research output: Contribution to journal › Comment/debate

Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials

International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group, Shi, Q., Paiva, B., Pederson, L. D., Dimier, N., Talpes, E., Prior, T. J., Orfao, A., Moreau, P., Sonneveld, P., Kumar, S. K., Dixon, J. G., Patel, R., Bartlett, B. J., Schecter, J., McCarthy, P., Hose, D., Seckinger, A., Mattia, DA., Goldschmidt, H., & 6 othersOliva, S., Owen, R. G., Anderson, K. C., San-Miguel, J., Durie, B. G. M. & Munshi, N., 10 Apr 2025, In: Journal of Clinical Oncology. 43, 11, p. 1289-1301 13 p.

Research output: Contribution to journal › Article › peer-review

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma

Hose, D., Ray, S., Rößler, S., Thormann, U., Schnettler, R., de Veirman, K., El Khassawna, T., Heiss, C., Hild, A., Zahner, D., Alagboso, F., Henss, A., Beck, S., Emde-Rajaratnam, M., Burhenne, J., Bamberger, J., Menu, E., de Bruyne, E., Gelinsky, M., Kampschulte, M., & 6 othersRohnke, M., Wenisch, S., Vanderkerken, K., Hanke, T., Seckinger, A. & Alt, V., 18 Dec 2024, In: Journal of Hematology & Oncology. 17, 1, 20 p., 128.

Research output: Contribution to journal › Article › peer-review

Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial

Salwender, H., Weinhold, N., Benner, A., Miah, K., Merz, M., Haenel, M., Jehn, C., Mai, E., Menis, E., Blau, I., Scheid, C., Hose, D., Seckinger, A., Luntz, S., Besemer, B., Munder, M., Brossart, P., Glass, B., Lindemann, H-W., Weisel, K., & 6 othersHanoun, C., Schnitzler, P., Klemm, S., Goldschmidt, H., Raab, M. & Elmaagacli, A., Dec 2024, In: Hematology (Amsterdam, Netherlands). 29, 1, 7 p., 2320006.

Research output: Contribution to journal › Article › peer-review

Modeling Myeloma Dissemination In Vitro with hMSC-interacting Subpopulations of INA-6 Cells and Their Aggregation/Detachment Dynamics

Kuric, M., Beck, S., Schneider, D., Rindt, W., Evers, M., Meißner-Weigl, J., Zeck, S., Krug, M., Herrmann, M., Hartmann, T. N., Leich, E., Rudert, M., Docheva, D., Seckinger, A., Hose, D., Jundt, F. & Ebert, R., 29 Apr 2024, In: Cancer research communications. 4, 4, p. 1150-1164 15 p.

Research output: Contribution to journal › Article › peer-review